PharmAla to supply Amsterdam UMC with LaNeo MDMA

PharmAla (MDXXF) Biotech executed a binding supply agreement with Amsterdam University Medical Center in the Netherlands for the provision of LaNeo 40mg MDMA capsules for use in a proposed clinical trial. Under the terms of the agreement, PharmAla will supply its LaNeo 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year stability testing program for the single-capsule dosage form, which will generate new stability data that PharmAla expects to leverage in the development of commercial-grade blister packaging for its LaNeo MDMA product line. The stability data generated under this agreement is expected to provide critical support for PharmAla’s broader commercial strategy. Single-capsule stability data is a prerequisite for the development of blister packaging, which represents the commercial standard for pharmaceutical distribution. PharmAla anticipates that the data collected through this program may be bridged into the generation of new commercial-grade blister packaging for its LaNeo MDMA product, potentially enabling more efficient distribution to clinical trial sites and commercial partners globally.